Proprietary Bioavailability Technology Stack

Proprietary High-Bioavailability Supplement Technology

Olympia Biosciences™ operates the most advanced formulation technology stack in European contract manufacturing: liposomal encapsulation, nano-micellization for poorly soluble compounds, enteric-coated DRcaps for pH-sensitive protection, and proprietary AI cocktail-effect elimination — all HPLC/GC-MS verified per batch.

Request a Technology Briefing Softgel Manufacturing ›

Liposomal Supplement Contract Manufacturing

Liposomal technology represents one of the most significant advances in oral bioavailability enhancement. By encapsulating active compounds within phospholipid bilayer vesicles that mimic human cell membranes, liposomal delivery systems protect sensitive molecules from gastric degradation and dramatically increase cellular uptake. As a liposomal supplement contract manufacturer, Olympia Biosciences™ engineers bespoke liposomal matrices for compounds ranging from fat-soluble vitamins and curcuminoids to NAD+ precursors and complex phytochemicals.

Our liposomal production process is not a simple mixing operation. We use computationally mapped lipid geometries to optimize vesicle size, lamellarity, and surface charge for each specific active ingredient. Every batch undergoes particle size analysis and encapsulation efficiency testing to ensure consistent therapeutic delivery.

Nano-Micellization Supplement Production

Many of the most potent bioactive compounds in nature are classified as "brick-dust" molecules — large, highly hydrophobic structures with oral bioavailability often below 5%. Standard tablets and capsules simply pass these compounds through the digestive tract unabsorbed. Nano-micellization solves this problem by reducing hydrophobic crystal structures into water-dispersible nanoparticles, typically in the 20-200nm range.

Olympia Biosciences™ operates high-shear nanomicellization systems guided by computational analysis of molecular geometry. This process forces direct cellular penetrance and systemic distribution of compounds that would otherwise be pharmacologically inert in standard oral dosage forms. Our nano-micellization technology is particularly effective for flavonoids, carotenoids, coenzyme Q10, and cannabinoid-class molecules.

Enteric Coated Capsules Contract Manufacturing

Certain active compounds — particularly probiotics, enzymes, and pH-sensitive botanicals — require protection from stomach acid to reach their site of action in the intestine. As an enteric coated capsules contract manufacturer, we apply precision polymer coatings that resist dissolution at gastric pH (1.5-3.5) while releasing their payload at intestinal pH (6.0-7.4). This targeted delivery approach is essential for clinical-grade probiotic formulations, pancreatic enzyme supplements, and delayed-release therapeutic compounds.

Premium Softgel Contract Manufacturing in Europe

Softgel capsules remain the gold standard for delivering lipid-soluble compounds, omega fatty acids, and oil-based formulations. Our premium softgel contract manufacturing in Europe produces both standard gelatin and plant-based (HPMC) softgels, with precise fill weight control and hermetic sealing that protects oxygen-sensitive ingredients. We support both standard oval formats and innovative shapes for brand differentiation.

Clean Label Supplement Manufacturing

The clean label movement reflects a legitimate demand for transparency in supplement manufacturing. Olympia Biosciences™ supports clean label formulation by minimizing excipients, avoiding artificial colors and flavors, and using plant-based capsule shells where appropriate. Our clean label supplement manufacturing capabilities include allergen-free production runs, non-GMO sourcing verification, and organic-compatible processing — all without compromising bioavailability or stability.

AI-Verified Formulation Safety

Every formula at Olympia Biosciences™ is designed from scratch by our R&D scientists. But we go further than any other CDMO: after human experts complete the formulation, our proprietary AI system — trained on a vast corpus of clinical pharmacology literature — performs an additional verification layer, the same risk-mitigation approach used in pharmaceutical drug development (as featured in

Delivery System Verification

After our scientists select the delivery system, AI cross-checks molecular properties of each active ingredient against the chosen method — liposomal, nano-micellar, enteric-coated, or matrix-embedded — confirming optimal absorption at the target tissue.

Cocktail Effect Elimination

Multi-ingredient formulations risk negative interactions between compounds. Our AI screens every combination against known pharmacological interactions, eliminating the cocktail effect before production begins.

Stability Prediction

The system predicts shelf-life stability based on ingredient chemistry, excipient compatibility, and packaging conditions — reducing the need for extended real-time stability studies and accelerating time-to-market.

HPLC-Tested Supplement Manufacturing

Every product manufactured by Olympia Biosciences™ undergoes analytical verification using High-Performance Liquid Chromatography (HPLC) and Gas Chromatography-Mass Spectrometry (GC-MS). This is not optional quality control — it is a mandatory step in our production protocol. We verify the exact concentration of active compounds in the finished product, confirming that what appears on the label is precisely what the patient receives. As an HPLC-tested supplement manufacturer, we provide comprehensive Certificates of Analysis (CoA) that are honored by regulatory authorities and customs agencies worldwide.

Our Pledge

We do not own consumer brands. We never compete with our clients.

Every formula created at Olympia Biosciences™ is built from scratch and transferred to you with full intellectual property ownership. Zero conflict of interest — guaranteed by ISO 27001 and iron-clad NDAs.

Explore Our Formulation Capabilities

From liposomal encapsulation to AI-verified safety screening — discover the technology behind high bioavailability supplement manufacturing.

Request a Technology Briefing

Frequently Asked Questions

What is liposomal supplement manufacturing?

Liposomal supplement manufacturing encapsulates active ingredients within phospholipid bilayer vesicles that mimic human cell membranes. This protects sensitive molecules from gastric degradation and dramatically increases cellular uptake and bioavailability.

What is nano-micellization in supplement production?

Nano-micellization reduces hydrophobic compounds into water-dispersible nanoparticles (typically 20-200nm range), solving the bioavailability problem of poorly absorbed ingredients like curcumin, CoQ10, and resveratrol.

How does AI-verified formulation safety work?

Our proprietary AI system screens every formulation for potential ingredient interactions, cocktail effects, and toxicological risks by analyzing vast databases of pharmacological and toxicological literature.

What are DRcaps® and how do enteric-coated capsules protect supplement bioavailability?

DRcaps® (Delayed Release capsules) are hard capsules with a special enteric polymer coating that remains intact in the acidic stomach environment and dissolves in the neutral pH of the small intestine. This protects acid-sensitive probiotics, digestive enzymes, omega-3 fatty acids, and peppermint oil from gastric destruction. We manufacture enteric-coated capsules to USP dissolution specifications.

What bioavailability advantages does liposomal delivery provide over standard supplements?

Liposomal delivery systems can increase bioavailability of poorly absorbed compounds by 2–10x compared to standard oral formulations. The phospholipid bilayer structure mimics cell membranes, enabling direct cellular uptake bypassing enterohepatic limitations. Clinical studies on liposomal vitamin C, glutathione, and curcumin demonstrate significantly higher plasma concentrations vs. equivalent conventional doses.

Can Olympia Biosciences™ develop a completely novel proprietary delivery technology for my supplement brand?

Yes. Our R&D team, led by a technical physicist and PhD candidate in medicine, develops bespoke bioavailability solutions for complex molecular challenges. We have co-developed the world's first plant-based collagen analog (Vegicoll®, registered trademark) and scaled Cambridge University's proprietary micellar technology to industrial production. Proprietary delivery technology represents a defensible competitive moat that cannot be replicated by competitors.

Strictly B2B / Educational R&D Disclaimer

The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.

Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.

Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ bears full and sole responsibility for all regulatory compliance, health claim authorization (including EFSA Article 13/14 claim dossiers and U.S. FDA notifications), labeling, and marketing of their finished product in their target market(s). Olympia Biosciences™ provides manufacturing, formulation, and analytical services only.